The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug
In short
Shares of Summit Therapeutics declined following guidance from the U.S. Food and Drug Administration regarding its lung-cancer drug. The agency recommended that the biotechnology company conduct a new clinical trial for the treatment. This downward movement intensified after a regulatory disclosure provided far more extensive details than what Summit Therapeutics had shared the prior Sunday.
Key points
- Federal health regulators have recommended an additional clinical study for the lung-canc…: Federal health regulators have recommended an additional clinical study for the lung-cancer treatment.
- Investor confidence weakened as official regulatory statements provided more details than…: Investor confidence weakened as official regulatory statements provided more details than the company disclosed.
- The biotechnology firm faces renewed pressure on its equity valuation following the agenc…: The biotechnology firm faces renewed pressure on its equity valuation following the agency's trial guidance.